~~<i id='2CD6784890'><strike id='2CD6784890'><tt id='2CD6784890'><pre id='2CD6784890'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：comprehensive 2025-10-01 04:14:03 - browse：72

An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.

The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Republican states more likely to report Covid vaccine side effects

explore

entertainment

Wikipedia

knowledge

hotspot

focus

RodrigoAbd/APTexashealthofficialsreportedMondaythatanindividualwhohadbeenincontactwithcattlehascontr

WSS

Drug companies' payments and gifts affect physicians' prescribing

Scientific mystery highlights the blind spots in genomics databases

Scientists inch closer to single

Adults seen as increasingly susceptible to measles

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Young boy dies in trial for Pfizer Duchenne gene therapy

focus

leisure time

explore

Virginia high school admissions case could be legal follow

Mega Millions pot grows to $1.25 billion after no winner

Hepatitis C has a cure — but many Americans still lack access to it

Mega Millions pot grows to $1.25 billion after no winner

Medical leaders decry Supreme Court decision on affirmative action

Bird flu reported in person exposed to presumably infected cattle

Psychedelics group wrestles with new pharma identity

What the US credit downgrade means for the economy, your finances

Heart attack and stroke risk calculators need revising

Physician groups backed by private equity giant lobby on mergers

entertainment

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

‘Oppenheimer’ and the risks of AI in health care

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Micronoma's microbiome cancer diagnostic approach under fire

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Oral obesity drug from Viking Therapeutics hits key early target

Wikipedia

knowledge

hotspot

focus